Skip to main content
. 2016 Feb 22;7(11):11756–11769. doi: 10.18632/oncotarget.7598

Figure 4. Targeting xCT suppresses MUC1 expression.

Figure 4

A. and B. MDA-MB-468 (A) or BT-20 (B) cells were treated with 1.0 μM or 1.5 μM SASP for 72 h, respectively. MUC1 mRNA levels were determined by qRT-PCR (left). The results (mean±SD of 4 determinations) are expressed as relative MUC1 mRNA levels as compared with that obtained for the untreated control cells (assigned a value of 1). Lysates from control and SASP-treated cells were immunoblotted with the indicated antibodies (right). C. and D. MDA-MB-468 (C) and BT-20 (D) cells were transfected to stably express a control shRNA (CshRNA) or an xCT shRNA (xCTshRNA). MUC1 mRNA levels were determined by qRT-PCR (left). The results (mean±SD of 4 determinations) are expressed as relative MUC1 mRNA levels as compared with that obtained for the CshRNA cells (assigned a value of 1). Lysates were immunoblotted with the indicated antibodies (right).